Emerson to Automate New Plant for First MAb Drugs In China
Emerson Process Management (St. Louis, MO) has been chosen to automate the first Chinese plant to produce monoclonal antibody drugs.
Emerson Process Management (St. Louis, MO) has been chosen to automate the first Chinese plant to produce monoclonal antibody drugs. The plant, owned by Shanghai CP Guojian Pharmaceutical Company and located in the Zhangjiang Hi-Tech Park in Shanghai, China, will have the largest mammalian cell-culture system in Asia. Monoclonal antibody drug production is expected to begin in August of this year.
The automation approach will include Emerson’s “PlantWeb” architecture with Foundation fieldbus instrumentation and the DeltaV digital automation system.
The Emerson solution is intended to meet the end-user's goal of applying advanced technology to all phases of pharmaceutical production while keeping costs low, meeting the construction schedule, and achieving a smooth start-up. Company officials expect to meet international standards with the products manufactured at this facility.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
